{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG002"],"nonInferiorityComment":"The study was designed as a standard dose-escalation study, dose-finding pilot study. The primary outcome measures were safety (hypercalcemia, hypophosphatemia and symptoms/hemodynamic measurements). A modified Fibronacci dose-escalation scheme was employed.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","pValue":">0.05","pValueComment":"The reported p-value corresponds to change over time for the PTHrP 2 and PTHrP 5 pmol groups","statisticalComment":"The level of statistical significance was set at .05 (two-tailed)","statisticalMethod":"Mixed Models Analysis","testedNonInferiority":true},{"ciNumSides":"TWO_SIDED","groupIds":["OG001"],"nonInferiorityComment":"The study was designed as a standard dose-escalation study, dose-finding pilot study. The primary outcome measures were safety (hypercalcemia, hypophosphatemia and symptoms/hemodynamic measurements). A modified Fibronacci dose-escalation scheme was employed.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","pValue":"0.01","pValueComment":"the reported p value corresponds to a decrease by Day 8 compared to baseline in the PTHrP 4 pmol group","statisticalComment":"The level of statistical significance was set at .05 (two-tailed)","statisticalMethod":"Mixed Models Analysis","testedNonInferiority":true}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.03","value":"34.13"},{"groupId":"OG001","spread":"4.24","value":"45.08"},{"groupId":"OG002","spread":"4.09","value":"39.0"}]}],"title":"baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.12","value":"38.40"},{"groupId":"OG001","spread":"1.53","value":"45.88"},{"groupId":"OG002","spread":"2.69","value":"39.77"}]}],"title":"Day 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.57","value":"30.13"},{"groupId":"OG001","spread":"4.17","value":"36.58"},{"groupId":"OG002","spread":"2.75","value":"36.73"}]}],"title":"Day 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.32","value":"32.23"},{"groupId":"OG001","spread":"4.18","value":"40.38"},{"groupId":"OG002","spread":"2.63","value":"35.17"}]}],"title":"Day 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.80","value":"32.27"},{"groupId":"OG001","spread":"6.12","value":"46.40"},{"groupId":"OG002","spread":"3.79","value":"32.07"}]}],"title":"Day 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.23","value":"42.77"},{"groupId":"OG001","spread":"4.91","value":"34.90"},{"groupId":"OG002","spread":"2.98","value":"35.37"}]}],"title":"Day 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.38","value":"40.53"},{"groupId":"OG001","spread":"3.58","value":"37.12"},{"groupId":"OG002","spread":"6.84","value":"31.17"}]}],"title":"Day 7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.17","value":"32.37"},{"groupId":"OG001","spread":"3.13","value":"33.43"},{"groupId":"OG002","spread":"4.79","value":"30.63"}]}],"title":"Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.01","value":"40.10"},{"groupId":"OG001","spread":"4.72","value":"45.78"},{"groupId":"OG002","spread":"2.11","value":"36.33"}]}],"title":"follow-up"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"description":"pg/ml","dispersionType":"Standard Error","groups":[{"description":"PTHrP(1-36) 2 picomoles/kg/hr for one week.","id":"OG000","title":"Group 1"},{"description":"PTHrP(1-36) 4 picomoles/kg/hr for one week.","id":"OG001","title":"Group 2"},{"description":"PTHrP(1-36) 5 picomoles/kg/hr for one week.","id":"OG002","title":"Group 3"},{"description":"PTHrP(1-36) 6 picomoles/kg/hr for one week.","id":"OG003","title":"Group 4"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Baseline and Daily through day 8 then at follow-up visit","title":"1,25 Vitamin D","type":"SECONDARY","unitOfMeasure":"pg/ml"}